Journal
FRONTIERS IN PHARMACOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2018.00325
Keywords
Parkinson's disease; amyotrophic lateral sclerosis (ALS); multiple sclerosis; neurodegeneration; ataxia; Huntington's disease; restless leg syndrome; purinergic receptors
Categories
Funding
- Sao Paulo State Foundation FAPESP [2012/50880-4]
- National Research Council CNPq, Brazil [306429/2013-6]
- CNPq [141979/2014-3, 870458/1997-3]
- FAPESP [2012/20685-5, 2013/25338-4, 2015/194783, 2015/14343-2]
Ask authors/readers for more resources
Since proving adenosine triphosphate (ATP) functions as a neurotransmitter in neuron/glia interactions, the purinergic system has been more intensely studied within the scope of the central nervous system. In neurological disorders with associated motor symptoms, including Parkinson's disease (PD), motor neuron diseases (MND), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Huntington's Disease (HD), restless leg syndrome (RLS), and ataxias, alterations in purinergic receptor expression and activity have been noted, indicating a potential role for this system in disease etiology and progression. In neurodegenerative conditions, neural cell death provokes extensive ATP release and alters calcium signaling through purinergic receptor modulation. Consequently, neuroinflammatory responses, excitotoxicity and apoptosis are directly or indirectly induced. This review analyzes currently available data, which suggests involvement of the purinergic system in neuro-associated motor dysfunctions and underlying mechanisms. Possible targets for pharmacological interventions are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available